The DIAPH3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung epithelial carcinoma line. This heterogeneous pool harbors targeted DIAPH3 gene disruptions, enabling studies of population-level effects of formin-3 loss. The knockout abrogates expression of Diaphanous-related formin-3, a critical actin nucleation factor, providing a system to investigate DIAPH3 function in a cancer cell context.
The A-549 cell line, originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma, is a widely used model for non-small cell lung cancer (NSCLC). These adherent epithelial cells display hallmark features, including aberrant proliferation, migration, and invasion. A-549 cells are a robust, genetically tractable platform for dissecting cancer-relevant pathways and metastatic mechanisms.
DIAPH3 belongs to the formin family of actin nucleators, assembling linear actin filaments at focal adhesions and the cell cortex. It is activated by Rho GTPases (RhoA, Rac1, Cdc42) and EGFR signaling. DIAPH3 recruits profilin and actin monomers for polymerization and interacts with APC and CLIP-170 to coordinate microtubule dynamics. Downstream, it organizes F-actin, microtubules, and focal adhesion components FAK and paxillin. These activities place DIAPH3 in the RhoA?CROCK?CDIAPH3?CF-actin axis that interfaces with YAP/TAZ in the Hippo pathway, regulating cytoskeletal remodeling, adhesion, and motility.
In A-549 cells, DIAPH3 knockout impairs actin cytoskeletal dynamics, attenuating lamellipodial protrusion, migration, and invasion??processes essential for metastasis. As DIAPH3 is implicated in lung adenocarcinoma, prostate cancer, and breast cancer progression, this model addresses metastatic research needs. It also allows exploration of mechanotransduction and EMT by linking Rho GTPase and Hippo signaling. The polyclonal design mimics tumor heterogeneity, facilitating modifier screening and population-level phenotypic analyses.
This model is compatible with routine assays: western blotting confirms DIAPH3 protein loss; immunofluorescence visualizes F-actin organization; RT-qPCR quantifies transcript knockdown; and transwell or wound?healing assays measure migration. Co-immunoprecipitation reveals disrupted DIAPH3?Cactin interactions, while RhoA activity assays assess upstream signaling. Applications extend to drug discovery for cytoskeletal regulators and anti?metastatic compounds. For ordering and inquiries, contact Ascent Research.
